Apotex supports launch of home-based cancer care with $1.5M donation
Oct 8, 2025Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
Cancer Care at Home combines remote monitoring, urgent oncology support and hospital-to-home services to create a seamless care pathway. The program aims to reduce emergency visits, ease transitions after hospital stays and provide guidance between appointments.
"Apotex is excited to support the launch of this innovative program that puts patients at the center and allows them to receive care where they are most comfortable," says Allan Oberman, President and CEO of Apotex. "Our team is committed to supporting those on their journey of health and enabling care at home. Patients and their families will truly benefit from this program and we are honoured to partner with Sunnybrook to make it possible."
This initiative reflects Apotex's commitment to expanding access to patient-centred care and supporting healthier communities. It also reinforces our role as a trusted partner in advancing innovative healthcare solutions.
Learn more about Cancer Care at Home and read the full press release here.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.